Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
CAS NO.1370003-76-1
yk11 Basic information |
Product Name: | yk11 |
Synonyms: | YK-11-OA |
CAS: | 1370003-76-1 |
MF: | C23H31ClN4O3S |
MW: | 0 |
Advantages
· Government supports, which guarantees better company credibility and finance safe.
· Fully free sample. Finerchem is confident at the quality of the products, it is gald to supply samples for final customers.
· Factory is in national new materials industry park where guarantees safe and international standard production environment. Welcome to visit our factory.
· More than 10 years chemical products exported experience, and good relationship with customs and shipment agents, it is easy for us to clear customs and arrange delivery by sea, air and courier.
· Professional R&D technology and equipments which keep products quality better and better.
What is YK11
(17α,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), which the myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist. as well as by dihydrotestosterone (DHT).
YK11 is a selective androgen receptor modulator (SARM), which activates AR without the N/C interaction. In this study, we further investigated the mechanism by which YK11 induces myogenic differentiation of C2C12 cells. The induction of key myogenic regulatory factors (MRFs), such as myogenic differentiation factor (MyoD), myogenic factor 5 (Myf5) and myogenin, was more significant in the presence of YK11 than in the presence of DHT. YK11 treatment of C2C12 cells, but not DHT, induced the expression of follistatin (Fst), and the YK11-mediated myogenic differentiation was reversed by anti-Fst antibody.
Myogenic differentiation is in reference to the products ability to block myostatin. Myostatin inhibition has been a really popular movement since the ban of most prohormones as it looks to be a relatively unexplored area for muscle growth and fat loss. There are currently a lot of claims about mystatin inhibition, but not so much factual data on these products. YK11 will have similar affects to DHT (possibly more potent) without the negatives of DHT. What this means is that the product will most likely be suppressive and require a post cycle, but not cycle support. It also won’t have androgenic side affects like hair loss, acne, etc. The increase in follistatin caused byYK11 will act as an antagonist to mystatin (it will block myostatin) as well as the anabolic growth properties of YK11.